Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis
Joseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
The Lancet. HIV
|
March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Chloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Infectious Diseases and Therapy
|
September 15, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod
Sharon A Riddler, Constance A Benson, Cynthia Brinson, et al.
Retrovirology
|
November 30, 2016
First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses
Eunsil Choi, Chad J Michalski, Seung Ho Choo, et al.
Best Practice & Research. Clinical Haematology
|
December 13, 2023
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry
Lucy C Fox, Zoe K McQuilten, Frank Firkin, et al.
The Lancet. Infectious Diseases
|
November 6, 2015
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Anthony Mills, Jose R Arribas, Jaime Andrade-Villanueva, et al.
Science Translational Medicine
|
June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
Devi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2020
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1
Sharon A Riddler, Michael Para, Constance A Benson, et al.
The Lancet. HIV
|
July 15, 2024
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial
David A Wohl, Christoph D Spinner, Jason Flamm, et al.
Open Forum Infectious Diseases
|
September 4, 2024
First Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care
Catherine A Koss, Monica Gandhi, Elias K Halvas, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis
Joseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
The Lancet. HIV
|
March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Chloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Infectious Diseases and Therapy
|
September 15, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod
Sharon A Riddler, Constance A Benson, Cynthia Brinson, et al.
Retrovirology
|
November 30, 2016
First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses
Eunsil Choi, Chad J Michalski, Seung Ho Choo, et al.
Best Practice & Research. Clinical Haematology
|
December 13, 2023
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry
Lucy C Fox, Zoe K McQuilten, Frank Firkin, et al.
The Lancet. Infectious Diseases
|
November 6, 2015
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Anthony Mills, Jose R Arribas, Jaime Andrade-Villanueva, et al.
Science Translational Medicine
|
June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
Devi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2020
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1
Sharon A Riddler, Michael Para, Constance A Benson, et al.
The Lancet. HIV
|
July 15, 2024
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial
David A Wohl, Christoph D Spinner, Jason Flamm, et al.
Open Forum Infectious Diseases
|
September 4, 2024
First Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care
Catherine A Koss, Monica Gandhi, Elias K Halvas, et al.
Page
of 6